# Governing the AI–biotech convergence: The rapid progress in and the dual-use nature of biotechnology and AI requires adaptive and resilient regulatory frameworks to address potential risks **Authors:** Benjamin D Trump, Christopher L Cummings, Beth Ellinport, Stephanie Galaitsi, Thomas Janisko, Elizaveta Pinigina, Hannah Herzig, Cindy S Groff-Vindman, Markus Schmidt, Gerald Epstein, Ruth Mampuys, Christian Haggenmiller, Tatyana Novossiolova, Travis Tubbs, James H Lambert, Alexander Titus, Igor Linkov PMC · DOI: 10.1038/s44319-025-00628-w · 2026-01-03 ## TL;DR This paper discusses the need for strong regulations to manage the risks of combining AI and biotechnology. ## Contribution The paper emphasizes the need for adaptive governance frameworks to address ethical and security risks in AI-biotech convergence. ## Key findings - AI and biotechnology convergence brings ethical and security risks. - Adaptive governance is needed to manage these risks responsibly. ## Abstract The convergence of artificial intelligence with biotechnology accelerates innovation but also introduces significant ethical and security risks. These require adaptive, flexible governance strategies that ensure that breakthroughs can be managed responsibly while mitigating potential risks. ## Full-text entities - **Diseases:** DL (MESH:D007859), DBTL (MESH:D013736), toxicity (MESH:D064420) - **Species:** Homo sapiens (human, species) [taxon 9606] ## Figures 1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12852783/full.md --- Source: https://tomesphere.com/paper/PMC12852783